The anti‐TNF monoclonal antibodies infliximab and adalimumab have transformed the management of immune‐mediated inflammatory diseases (IMIDs), including inflammatory bowel disease (IBD).1 The gene discussed is TNF; the disease is inflammatory bowel disease.